Evidence of Mpox Virus Infection Among Persons Without Characteristic Lesions or Rash Presenting for First Dose of JYNNEOS Vaccine—District of Columbia, August 2022

Baird, Nicolle; Townsend, Michael; Berry, Isha; Griffin, Isabel; Ashley, Patrick; Wynn, Nhien T.; Kling, C.; Smith, T.; Priyamvada, Lalita; Carson, William C.; Navarra, Terese; Dawson, Patrick; Weidle, Paul J.; Willut, Christina; Mangla, Anil T.; Satheshkumar, Panayampalli S.; Hutson, Christina L.; Jackson, David A.; Waltenburg, Michelle A.; Ahmad, Ashfaq; Armstrong, Jaia; Brake, Marie; Bunkley, Paige; Callaway, Perri C.; Chakrabarti, Ayan K.; Folster, Jennifer; Forero, Catalina; Furness, Bruce W.; Godino, Claire; Greenberg, L.; Guagliardo, Sarah Anne J.; Jadhao, Samadhan; Jordan, Teskisha; Kamitani, Emiko; Keino, Barbara; Kopping, Erik; Lee, Joo Sang; Lopez, Leah; Lowe, David; Metz, John; Miko, Shanna; Mrotz, Victoria; Noiman, Adi; Partin, James; Pearce, Melissa Brykailo; Pettus, Kevin; Rodríguez, S.; Sabin, Susanna; Santo, Loredana; Schrodt, Caroline A.; Sharma, Pankaj; Shelus, Victoria; Shi, Dallas; Sodeke, Olutomi; Springstubb, Nora; Stager, Christan Halverson; Stewart, Roxana Rodriguez; Tang, Xiaoling; Tertuliano, M.; Timm, Logan; Vantucci, Casey E.; Vaughan, Gilberto; Wondmeneh, Sarah; Yang, Yong; Anthony, Eric Tobechukwu; Argyriou, Marie; Ayuk-Takor, Leslie; Bryant, Miriam F.; Cherrix, Angela; Coleman, David C.; Cunningham, Carole; Dastidar, Ronit; Dato, Olivia; Elnour, Azam; Gillani, Sarah; Hartley, Tracie; Israel, Dionnie; Lee, Michelle; McCullam, Susan; Meh, Ie; Notigan, Tiffany; Rajamohan, Saumya; Rhodes, Trevor; Rosado, Blanca; Rowse, Julia; Shapiro, Brandon; Smart, Kristen; Staff, Michael; Taylor, Jaketia; Webb, Ricardo; White, Rajanique; Widatalla, Saria; Wilson, Shanice

doi:10.1093/cid/ciad145

Cited by 11 publications

(12 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During August 11–31, 2022, we recruited individuals to participate during their first dose after vaccination waiting period. We described the larger investigation, 8 determined eligibility, and obtained informed consent. Participants were asked to attend 3 clinic visits across 2 months (days 0 [first dose], 28 [second dose], and 42 [2 weeks after second dose]) for the larger study 8 .…”

Section: Methodsmentioning

confidence: 99%

“…We described the larger investigation, 8 determined eligibility, and obtained informed consent. Participants were asked to attend 3 clinic visits across 2 months (days 0 [first dose], 28 [second dose], and 42 [2 weeks after second dose]) for the larger study 8 . Participants completed a self-administered survey at each visit.…”

Section: Methodsmentioning

confidence: 99%

“…Participants were asked to attend 3 clinic visits across 2 months (days 0 [first dose], 28 [second dose], and 42 [2 weeks after second dose]) for the larger study. 8 Participants completed a self-administered survey at each visit. Those who completed a self-administered survey at their first and second dose visits were included in the quantitative analysis of this study.…”

Section: Recruitmentmentioning

confidence: 99%

“…To inform mpox prevention strategies, during August-October 2022, we collected information on knowledge, attitudes, and practices related to mpox and mpox vaccine as part of a larger investigation to assess mpox prevalence and immune response in the District of Columbia (DC), which had seen more than 300 mpox cases by August 2022. 8,9 This analysis incorporated quantitative survey data with qualitative interview data to provide social context to findings and a person-centered approach to data collection and analysis. 10 We focused on perceptions of mpox and experiences with vaccine access to inform ongoing mpox prevention strategies and future outbreaks of similar infectious diseases.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Mpox Knowledge, Attitudes, and Practices Among Persons Presenting for JYNNEOS Vaccination—District of Columbia, August to October 2022

Hassan,

Wondmeneh,

Gonzalez Jimenez

et al. 2023

Sexual Trans Dis

Self Cite

View full text Add to dashboard Cite

Background More than 30,000 mpox cases have been confirmed in the United States since May 2022. Mpox cases have disproportionally occurred among adult gay, bisexual, and other men who have sex with men (MSM), transgender persons, and Black and Hispanic/Latino persons. We examined knowledge, attitudes, and practices regarding mpox vaccination among adults presenting for vaccination to inform prevention efforts. Methods We collected mixed-methods data from a convenience sample of adults presenting for JYNNEOS vaccination at three DC Health mpox vaccine clinics during August–October 2022. Survey and interview topics included knowledge about mpox symptoms and vaccine protection, beliefs about vaccine access, and trusted sources of information. Results In total, 352 participants completed self-administered surveys and 62 participants completed an in-depth interview (IDI). Three main themes emerged from survey and interview data. First, most participants had a general understanding about mpox, but gaps remained in comprehensive understanding about mpox symptoms, modes of transmission, vaccine protection, personal risk, and vaccine dosing strategies. Second, participants had high trust in public health agencies. Third, participants wanted more equitable and less stigmatizing access to mpox vaccine services. Conclusions Non-stigmatizing, inclusive, and clear communication from trusted sources, including public health agencies, is needed to address mpox knowledge gaps and increase vaccine access and uptake in affected communities. Mpox outreach efforts should continue innovative approaches, including person-level risk assessment tools, to address community needs.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Recruitmentmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Mpox Knowledge, Attitudes, and Practices Among Persons Presenting for JYNNEOS Vaccination—District of Columbia, August to October 2022

Hassan,

Wondmeneh,

Gonzalez Jimenez

et al. 2023

Sexual Trans Dis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Vaccinated patients diagnosed with clinical disease represent the expected percentage of vaccine failures, with vaccine efficacy approximating 85% [9] . Asymptomatic patients have also been involved [10] , raising the possibility of viral circulation. Our 15 patients could be but the tip of the iceberg.…”

mentioning

confidence: 99%

Resurgence of symptomatic Mpox among vaccinated patients: First clues from a new-onset local cluster

Simon

Lynda

Cathie

et al. 2023

Infectious Diseases Now

View full text Add to dashboard Cite

Serologic responses to the MVA-based JYNNEOS mpox vaccine in a cohort of participants from the District of Columbia (D.C.)

Griffin,

Berry,

Navarra

et al. 2024

Vaccine

View full text Add to dashboard Cite

Evidence of Mpox Virus Infection Among Persons Without Characteristic Lesions or Rash Presenting for First Dose of JYNNEOS Vaccine—District of Columbia, August 2022

Cited by 11 publications

References 7 publications

Mpox Knowledge, Attitudes, and Practices Among Persons Presenting for JYNNEOS Vaccination—District of Columbia, August to October 2022

Mpox Knowledge, Attitudes, and Practices Among Persons Presenting for JYNNEOS Vaccination—District of Columbia, August to October 2022

Resurgence of symptomatic Mpox among vaccinated patients: First clues from a new-onset local cluster

Serologic responses to the MVA-based JYNNEOS mpox vaccine in a cohort of participants from the District of Columbia (D.C.)

Contact Info

Product

Resources

About